A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PART I. BUSINESS We are a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. We are advancing two cell therapy platforms derived from the bone marrow in clinical trials today. Our CardiAMP® autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Our immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as an “off the shelf” cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO™), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -8.5M | -7.9M | -12M | -12M | -13M | -15M |
| EPS | $-1.42 | $-2.90 | $-122.85 | $-10.05 | $-11.25 | $-22.20 |
| Free Cash Flow | 0 | -8.0M | -10.0M | -11M | -10M | -12M |
| ROIC | -110.3% | -169.7% | -308.0% | -96.0% | -121.7% | -78.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.14 | -0.82 | 0.33 | 0.18 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -8.6M | -8.0M | -12M | -12M | -13M | -16M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -325.1% | -949.3% | - | -243.4% | -121.7% | -78.2% |
| Shares Outstanding | 11M | 3M | 0M | 1M | 1M | 1M |
BioCardia, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
BioCardia, Inc. (BCDA) has a 5-year average return on invested capital (ROIC) of -116.4%. This is below average and may indicate limited pricing power.
BioCardia, Inc. (BCDA) has a market capitalization of $13M. It is classified as a small-cap stock.
BioCardia, Inc. (BCDA) does not currently pay a regular dividend.
BioCardia, Inc. (BCDA) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
BioCardia, Inc. (BCDA) generated $-8 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
BioCardia, Inc. (BCDA) has a debt-to-equity ratio of 1.14. This indicates moderate leverage.
BioCardia, Inc. (BCDA) reported earnings per share (EPS) of $-2.90 in its most recent fiscal year.
BioCardia, Inc. (BCDA) has a return on equity (ROE) of -949.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for BioCardia, Inc. (BCDA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BioCardia, Inc. (BCDA) has a book value per share of $0.31, based on its most recent annual SEC filing.